Skip to main content
Premium Trial:

Request an Annual Quote

Proteona Licenses Sequencing-Based Protein Analysis Technology

NEW YORK (GenomeWeb) — Startup Proteona announced today that it has acquired an exclusive worldwide license to a novel sequencing-based technology for protein analysis from the National University of Singapore (NUS).

According to Proteona, the technology — called enhanced single-cell analysis with protein expression, or ESCAPE — uses DNA-barcoded antibodies to enable single-cell RNA sequencing platforms to detect and quantify protein expression. The resulting combination of RNA and proteomic data can be used to characterize cell populations based on surface markers and cellular genomic processes, the Singapore-based NUS spinout said.

Specific terms of the license were not disclosed.

"We have validated large sets of DNA barcoded antibodies that can be added to any single-cell RNA sequencing experiment," Proteona CEO Andreas Schmidt said in a statement. "Insights gained from multi-dimensional profiling of the immune system can aid therapeutic design and treatment approaches in oncology, hematology, [and] immunology, as well as autoimmune and other diseases."

Schmidt added that Proteona — which also maintains operations in San Diego — will work with customers to develop the bioinformatics tools required to analyze ESCAPE data.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.